IDEAYA Biosciences, Inc. IDYA Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

SPS CommerceSPSC

$4.87M+54.2%

AvePoint, Inc.AVPT

$4.39M+4.3%

Q2 HoldingsQTWO

$45.49M+26.0%

AMN HealthcareAMN

-$4.41M-312%

CalixCALX

$675K-80.6%

Rackspace Technology, Inc.RXT

$35.6M+483%

Other financials

Income statement

See full

Revenue$6.6M—

Operating income-$108.5M-28.6%

Net income-$98.5M-36.5%

EPS (diluted)-$1.11-35.4%

Balance sheet

See full

Cash & equivalents$157.5M+21.2%

Total debt$28.6M+10.1%

Total equity$937.3M-8.5%

Total assets$1.0B-6.4%

Cash flow

See full

Operating cash flow-$75.2M-24.6%

CapEx$967.0K-27.3%

Free cash flow-$76.1M-23.5%

Valuation

See full

Market cap$3.49B+104%

Enterprise value$3.36B+110%

P/S15×+10.3×

Profitability

See full

Operating margin-4,671.1%-5,434pp

Net margin-3,921.1%-4,562pp

FCF margin-3,592%-4,290pp

Returns & leverage

See full

Return on equity-14.3%-5.0pp

Debt / equity0×0.0×

Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s increase (decrease) in contract liabilities and current deferred income?: IDEAYA Biosciences, Inc. (IDYA) reported increase (decrease) in contract liabilities and current deferred income of -$587K in Q1 2026.
What is the long-term trend for IDEAYA Biosciences, Inc.'s increase (decrease) in contract liabilities and current deferred income?: Over 2 years (2021 to 2023), IDEAYA Biosciences, Inc.'s increase (decrease) in contract liabilities and current deferred income has grown at a -23.6% compound annual growth rate (CAGR), from -$23.54M to -$13.75M.